More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.87B
EPS
-2.79
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.936859
Previous close
$21.41
Today's open
$21.36
Day's range
$19.60 - $21.55
52 week range
$1.50 - $23.54
show more
CEO
Sushil Patel
Employees
465
Headquarters
Woburn, MA
Exchange
Nasdaq Global Select
Shares outstanding
94800404
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Wall Street Analysts Think Replimune Group (REPL) Could Surge 29.51%: Read This Before Placing a Bet
The consensus price target hints at a 29.5% upside potential for Replimune Group (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research • 42 minutes ago

REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress
Replimune shares surge 80% as Tudriqev's commercial launch gains traction, earnings beat expectations and pipeline progress strengthens growth prospects.
Zacks Investment Research • Nov 12, 2026

Short Interest Powder Kegs: 10 Stocks Bears Cannot Quit Buying
Bears are crowding into a small group of stocks, and one name has nearly its entire float sold short.
Benzinga • Nov 11, 2026

Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade
The mean of analysts' price targets for Replimune Group (REPL) points to a 26.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Research • Nov 2, 2026

Replimune: 3 Key Takeaways for Long-Term Investors
Replimune ended the second quarter with $307.8 million in cash. Over 15 institutions wrote prescriptions within 20 business days.
The Motley Fool • Oct 29, 2026

Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript
Replimune Group, Inc. ( REPL ) Q2 2027 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Arleen Goldenberg Sushil Patel - CEO & Director Michelle DiNapoli - Chief Commercial Officer Emily Hill - Chief Financial Officer Conference Call Participants Evan Seigerman - BMO Capital Markets Equity Research Allison Bratzel - Piper Sandler & Co., Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Jiale Song - Jefferies LLC, Research Division Mubeen Mosaheb Romy O'Connor - Van Lanschot Kempen NV Presentation Operator Good day, and thank you for standing by. Welcome to the Replimune's Second Quarter Fiscal 2027 Earnings Conference Call.
Seeking Alpha • Oct 28, 2026

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET WOBURN, Mass.
GlobeNewsWire • Oct 28, 2026

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET to discuss its financial results and provide corporate update for the fiscal second quarter ended September 30, 2026.
GlobeNewsWire • Oct 22, 2026

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Replimune (REPL) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/5/2026
GlobeNewsWire • Oct 5, 2026

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL
Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency letter and that commercial launch teams stood ready; the agency's April 2026 rejection letter stated the study design concerns it had previously communicated were never addressed, and REPL shares fell to $1.70. Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency letter and that commercial launch teams stood ready; the agency's April 2026 rejection letter stated the study design concerns it had previously communicated were never addressed, and REPL shares fell to $1.70.
GlobeNewsWire • Oct 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Replimune Group Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.